Email this article Comparative analysis of residual neurovirulence of vaccine and low attenuated rubella virus (Matonaviridae: Rubivirus: Rubella virus) strains in the experiments on the macaque rhesus (Macaca mulatta) monkeys
- Authors: Shamsutdinova O.A.1, Bulgin D.V.1, Karal-ogly D.D.1, Lavrentieva I.N.2, Klots I.N.1
-
Affiliations:
- FSBRI «Research Institute of Medical Primatology» of the Ministry of Education and Science of Russia
- FSBI «Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology» of the Federal Service for Surveillance on Consumer Rights Protection and Human Welfare (Rospotrebnadzor)
- Issue: Vol 67, No 2 (2022)
- Pages: 133-141
- Section: ORIGINAL RESEARCH
- URL: https://virusjour.crie.ru/jour/article/view/609
- DOI: https://doi.org/10.36233/0507-4088-97
- ID: 609
Cite item
Abstract
Introduction. Rubella is currently an infection controlled by specific prophylaxis. Not only the right vaccine prophylaxis strategy and tactics, but also the use of effective and safe vaccine preparations is crucial for the elimination of this disease.
The aim of the investigation was to study the morphological and pathogenetic patterns of changes developing in the central nervous system (CNS) and internal organs of monkeys (Haplorhini) during intracerebral inoculation with 2 strains of rubella virus (Matonaviridae: Rubivirus: Rubella virus) (RV): highly attenuated Orlov-B, and low attenuated Orlov-14.
Material and methods. In the experiments, seronegative rhesus macaque monkeys (Macaca mulatta) weighing 3.3–5.1 kg (n = 7) were used. Neurovirulence of the strains was determined by a complex of clinical, pathomorphological, and virological methods.
Results and discussion. It was found that during attenuation, the Orlov-B strain lost the ability to replicate in CNS cells and induce moderate/expressed specific changes in them, as well as to overcome the blood-brain barrier and cause the damage of sensitive organs and tissues. This fact indicates a low level of residual neurovirulence of the vaccine strain.
Conclusion. The results obtained in this study regarding the clinical symptoms of CNS lesions and the nature of the pathological process in its tissues in experimental animals can be significant for the improvement of safety control of live rubella vaccines. These data indicate that the Orlov-B strain can be considered as a candidate strain for further study on the development of a rubella vaccine based on the domestic vaccine strain.
About the authors
O. A. Shamsutdinova
FSBRI «Research Institute of Medical Primatology» of the Ministry of Education and Science of Russia
Author for correspondence.
Email: shamsutdinova-o-a@yandex.ru
ORCID iD: 0000-0002-2742-3965
Olga Anatolyevna Shamsutdinova, scientist, lab. immunology and cell biology
177 Mira str., Veseloe village, Sochi, Adler, 354376
Russian FederationD. V. Bulgin
FSBRI «Research Institute of Medical Primatology» of the Ministry of Education and Science of Russia
Email: molmed1999@yahoo.com
ORCID iD: 0000-0003-1739-8505
Dmitriy Viktorovich Bulgin - Ph.D. head of laboratory of pathological anatomy
177 Mira str., Veseloe village, Sochi, Adler, 354376
Russian FederationD. D. Karal-ogly
FSBRI «Research Institute of Medical Primatology» of the Ministry of Education and Science of Russia
Email: karal_5@mail.ru
ORCID iD: 0000-0003-3606-1668
Dgina Dginarovna Karal-ogly - Ph.D. depute of director
177 Mira str., Veseloe village, Sochi, Adler, 354376
Russian FederationI. N. Lavrentieva
FSBI «Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology» of the Federal Servicefor Surveillance on Consumer Rights Protection and Human Welfare (Rospotrebnadzor)
Email: pasteur.lawr@mail.ru
ORCID iD: 0000-0002-2188-6547
Irina Nikolaevna Lavrent'eva - Ph.D. Doctor of medical Sciences, head of laboratory of experimental virology
14 Mira str., Saint Petersburg, 197101
Russian FederationI. N. Klots
FSBRI «Research Institute of Medical Primatology» of the Ministry of Education and Science of Russia
Email: igor-imp@mail.ru
ORCID iD: 0000-0003-1025-3127
Igor Naumovich Klots - Ph.D. head of laboratory of immunology and cell biology
177 Mira str., Veseloe village, Sochi, Adler, 354376
Russian FederationReferences
- Bouthry E., Picone O., Hamdi G., Grangeot-Keros L., Ayoubi J.M., Vauloup-Fellous C. Rubella and pregnancy: diagnosis, management and outcomes. Prenat. Diagn. 2014; 34(13): 1246–53. https://doi.org/10.1002/pd.4467
- Saffar H., Khalifeloo M., Saffar M.J., Abdollahi A., Parsaei M.R., Ghorbani G.R., et al. Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran. BMC Infect. Dis. 2021; 21(1): 305. https://doi.org/10.1186/s12879-021-05970-7
- Di Pietrantonj C., Rivetti A., Marchione P., Debalini M.G., Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst. Rev. 2020; 4(4): CD004407. https://doi.org/10.1002/14651858.CD004407.pub4
- Terracciano E., Amadori F., Pettinicchio V., Zaratti L., Franco E. Strategies for elimination of rubella in pregnancy and of congenital rubella syndrome in high and upper-middle income countries. J. Prev. Med. Hyg. 2020; 61(1): E98-E108. https://doi.org/10.15167/2421-4248/jpmh2020.61.1.1310
- Croce E., Hatz C., Jonker Е.F., Visser L.G., Jaeger V.K., Bühler S. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation – A systematic review of randomized trials, observational studies and case reports. Vaccine. 2017; 35(9): 1216–26. https://doi.org/10.1016/j.vaccine.2017.01.048
- Миронов А.Н., ред. Руководство по проведению доклинических исследований лекарственных средств. Том 1. М.: Гриф и К; 2012.
- Yang M.H., Freitas A.R.R. Biological view of vaccination described by mathematical modellings: from rubella to dengue vaccines. Math. Biosci. Eng. 2019; 16(4): 3195–214. https://doi.org/10.3934/mbe.2019159
- Мешалова В.Н., Жукова Е.А., Степанов А.Н. Прививочные свойства краснушной вакцины из штамма «Орлов». В кн.: Детские вирусные инфекции: Труды Института Пастера. Ленинград; 1979: 112–5.
- Медуницын Н.В. Государственная система оценки безопасности вакцин. Вакцинация. Новости вакцинопрофилактики: информационный бюллетень. 2000; (8): 4–6.
- Лаврентьева И.Н., Сухобаевская Л.П., Жебрун А.Б. Штамм вируса краснухи для получения медицинских иммунобиологических препаратов (МИБП). Патент РФ № 2081912; 1995. Available at: https://www.freepatent.ru/patents/2492235.
- Общая фармакопейная статья ОФС.1.7.2.0010.15. Оценка специфической безопасности производственных штаммов и посевных вирусов кори, паротита и краснухи. Available at: https://nevacert.ru/reestry/pharmacopoeia/ofs.1.7.2.0010.15 (accessed February 2, 2022).
- Barrett J.R. Pediatric vaccines and neurodevelopment: primate study finds no adverse behavioral effects. Environ. Health Perspect. 2015; 123(6): A156. https://doi.org/10.1289/ehp.123-A156
- Curtis В., Liberato N., Rulien M., Morrisroe K., Kenney C., Yutuc V., et al. Examination of the safety of pediatric vaccine schedules in a non-human primate model: assessments of neurodevelopment, learning, and social behavior. Environ. Health Perspect. 2015; 123(6): 579–89. https://doi.org/10.1289/ehp.1408257
- Gadad B.S., Li W., Yazdani U., Grady S., Johnson T., Hammond J., et al. Administration of thimerosal-containing vaccines to infant rhesus macaques does not result in autism-like behavior or neuropathology. Proc. Natl. Acad. Sci. USA. 2015; 112(40): 12498– 503. https://doi.org/10.1073/pnas.1500968112
- Lapin B.A., Shevtsova Z.V. Monkey viral pathology in the Sukhum colony and modeling human viral infections. J. Med. Primatol. 2018; 47(4): 273–7. https://doi.org/10.1111/jmp.12351
- Lim F.S., Han H.H., Bock H.L. Safety, reactogenicity and immunogenicity of the live attenuated combined measles, mumps and rubella vaccine containing the RIT 4385 mumps strain in healthy Singaporean children. Ann. Acad. Med. Singap. 2007; 36(12): 969–73.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).